Skip to content

CDER DMF Workshop 2021 Banner

Drug Master File (DMF) and Drug Substance Workshop
March 3 & 4, 2021

Ensuring high quality and manufacturing integrity of Active Pharmaceutical Ingredients (APIs) requires understanding and incorporation of quality and risk management principals throughout the API lifecycle. This conference is designed to provide an update on current Agency initiatives and will cover a wide variety of topics of interest to API manufacturers and regulators. Specifically, the Agency wishes to provide guidance on the DMF submission process and expectations for content through a series of presentations, panel discussions, and Q&A for two poster sessions. The desired outcome is to outline the various regulatory steps necessary for the successful development of a high-quality submission of drug substance information to the Agency.

Agenda & Speaker Bios

PDF Download
Event Agenda

The agenda may be updated as changes to the schedule occur. The currents version is Version 4, updated on January 8, 2021.

PDF Download
Speaker Biographies

The speaker biographies document provides information on the speakers participating in the Workshop.

Files, Certificate & Recordings

ZIP of Follow-Up Webinar Slides

Session Recordings:

Day One:

Day Two:

Follow-Up Webinar Recordings:

Poster Presentations

In addition to the presentations during the 2-day Conference, there are 19 pre-recorded Poster Presentations on a variety of topics.

* Download PDFs of the Posters *


The Poster Presentations

View the

1. Timeline for the DMF review process (basic primer on how we align with ANDA)

Authors: Wei Song, Steve Kinsley. Alignment of the DMF review process with the ANDA review process and timelines will be covered.

View the Presentation

2. Completeness Assessments (CAs): Current CA Status, KASA for CA, Common Issues & GDUFA Commitment Letter Statistics

Authors: Yingzi Wang, Jayani R. Perera, Jason Crawford, Larisa Wu, and Xiang Yu. This poster discusses CA statistics, application of KASA, and advice for improving the CA outcome.

View the Presentation

3. Metrics on DMF Assessments

Authors: Steve Kinsley, Wei Song. DMF statistics including adherence to due dates and overall productivity will be presented.

View the Presentation

4. Introduction to FDA Drug Master File Form 3938

Authors: Vathsala Selvam and CDR David Skanchy. The new FDA DMF form 3938, similar to the application 356h form, will be presented. View full 29-minute full length webinar: Drug Master Files(DMF) Submissions on New FDA Form 3938

View the Presentation

5. Cocrystal APIs: Recommended Documentation

Authors: Weiqin Jiang, Neeru Takiar, and Ramnarayan Randad. A discussion of API sameness with regard to cocrystal APIs will be covered.

View the Presentation

6. Synthetic Therapeutic Polymers: Recommended documentation for API sameness

Authors: Bapu R. Gaddam, Ramnarayan Randad, Benjamin Lim, David Skanchy. Regulatory strategies to establish API sameness of cross coupled polymers.

View the Presentation

7. Synthetic Therapeutic Peptide APIs: Recommended documentation for API sameness & related impurities

Authors: Suresh Jayasekara, Manivannan Ethirajan, David Green, and Ramnarayan Randad. Practical advice on achieving API sameness in peptide drug substances is provided.

View the Presentation

8. Regulatory Considerations for Synthetic and Semi-synthetic Oligosaccharide Complex APIs in Generic Products

Authors: Keduo Qian, Barbara Scott, Govindaraj Kumaran, Weixiang Dai, CDR David Skanchy. We will present the Agency’s current thinking on the active ingredient sameness assessment of oligosaccharide complex APIs in generic and reference products.

View the Presentation

9. Quality Considerations for Continuous Manufacturing of APIs

Authors: Anjali Bain, Yun J. Wang, Ramnarayan Randad, David Skanchy, Adil Mohammad, Raymond Frankewich, and Thomas O’Connor. This poster is based on the draft guidance Quality Considerations for Continuous Manufacturing and provides information regarding FDA’s current thinking on the quality considerations for continuous manufacturing of small molecule drug substances.

View the Presentation

10. ANDA Aligned Teams

Authors: Steve Kinsley, Wei Song. The new Integrated Quality Assessment (IQA) alignment of teams to facility collaborative review will be presented.

View the Presentation

11. Review of Secondary Type II Drug Master Files

Authors: Madhusudhan Gowravaram & David Skanchy. This poster will discuss the risk-based review approach for the acceptance of secondary DMFs for the adequacy of primary DMFs supporting A/NDAs and some regulatory aspects of secondary DMFs.

View the Presentation

12. USP Pending Monograph Process and USP compliance for Industry

Authors: Yan Ma, Yun J. Wang, Anita Tiwari, Barbara Scott. This poster provides information on FDA’s current thinking on the USP-PMP and recommendations for drug master file (DMF) holders.

View the Presentation

13. Evaluation of Metal Impurities in Drug Substances

Authors: Donglei Yu, Mst Hasina Akter, Wei Liu, Ramnarayan Randad. The risk assessment for elemental impurities in drug substances and atypical drug substances will be discussed.

View the Presentation

14. Mutagenic Impurities from a Drug Substance Perspective: Highlights from the ICH M7 Question and Answer Draft Document

Authors: David Green, Barbara Scott, CDR David Skanchy. We will highlight four topics covered in the new ICH M7 Question and Answer Draft Document surrounding the control of mutagenic impurities.

View the Presentation

15. Establishing Impurity Acceptance Criteria as Part of Specifications for DMFs Based on Clinical Relevance

Authors: Yongjun Gao, Ramnarayan Randad, David Green, Weixiang Dai, Hongbiao Liao and David Skanchy. Advice on establishing impurity limits in various cases is provided.

View the Presentation

16. API Manufacturing Global Distribution and Facility Profile Analysis

Authors: Wei Song, Ying Zhang, Nathan Chen, and CDR David Skanchy. We will discuss the diverse and complex global API supply chain.

View the Presentation

17. Communications with DMF Holders and Applicants throughout the DMF Lifecycle

Authors: Fatima C. Sequeira, Vathsala Selvam, Claude Theophin, Terrence Nichols, Ben Danso, David Skanchy. We will review available pathways, that DMF holders and applicants can communicate with Agency.

View the Presentation

18. The DMF Teleconference Process

Authors: Benjamin Danso and Jayani Perera. The current process for requesting, granting, and executing a DMF teleconference will be described along with data and metrics for the process from GDUFA I to present.

View the Presentation

19. List of Relevant Quality Guidances & Common Deficiencies Observed during Drug Master File Review

Authors: Sad Ahamed and Mahmut Levent. This poster provides a non-exhaustive list of relevant technical guidance applicable to DMFs and discuss common deficiencies.

View the Presentation

Questions & More Information


Please refer the FAQs page on this website. If you are not able to find your answer there, please email us at

More Information

If you have questions regarding the content of the event or other CDER-specific information, please: